TrialNature communications2026

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

John H Strickler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.